MISSISSAUGA, ON, April 30, 2012 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it will be presenting its IV ClearTM line of antimicrobial clear silicone adhesive vascular access securement dressings from April 30th to May 2nd at the 2012 Infusion Nurses Society Annual Convention & Industrial Exhibition in Las Vegas ("INS").
"Our team is extremely excited to present our newest products that are designed to address the growing need for infection control, including Catheter Related Blood Stream Infections (CRBSI), for which the Center for Disease Control (CDC) calls one of the most deadly and costly threats to patient safety at this year's INS meeting," said Brian Pedlar, Covalon's Chief Executive Officer. "We are looking forward to introducing our new line-up of products to our growing domestic and international distribution channels and to medical product companies who are looking to license breakthrough new products."
In support of this breakthrough technology, Covalon's Dr. Liu Yang will present: A Novel Antimicrobial Clear Silicone Dressing with Chlorhexidine and Silver at the INS poster sessions. This data demonstrates the combined benefits of IV Clear's antimicrobial efficacy and patient friendly silicone adhesive, which for the first time ever is available within one intuitive dressing system.
The INS convention provides Covalon with the perfect opportunity to showcase its infusion care related products to 1,500 infusion nurses from 30 and close to 100 leading manufacturers, wholesalers and distributors.
Covalon will also be showcasing new medical device coatings, including its lubricious and antimicrobial coated catheters, which utilize its patented CovaCoat™ technology. These exciting new products will be available for license or distribution, following regulatory clearance.
To learn more about Covalon's products and services, please visit us at booth 227 in the Rio All-Suite Hotel & Casino from April 30th to May 2nd or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at firstname.lastname@example.org.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
For further information:
CEO, Covalon Technologies Ltd.
T: (905) 568-8400 x 233
F: (905) 568-5200